Cargando…

First Report of De Novo Nivolumab-Induced Oligoarthritis in a Young Man With Relapsing Classic Hodgkin Lymphoma

Detalles Bibliográficos
Autores principales:	Galdiero, Maria Rosaria, Morelli, Emanuela, Triggianese, Paola, Carucci, Laura, Punziano, Alessandra, Pinto, Antonio, Genovese, Arturo, de Paulis, Amato, Spadaro, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8746895/ https://www.ncbi.nlm.nih.gov/pubmed/32511147 http://dx.doi.org/10.1097/RHU.0000000000001459

Ejemplares similares

A case of de novo seronegative inflammatory oligoarthritis associated with COVID-19 infection
por: Sung, Lily H., et al.
Publicado: (2022)

Oligoarthritis Caused by Borrelia bavariensis, Austria, 2014
por: Markowicz, Mateusz, et al.
Publicado: (2015)

Immunosuppressive therapy with rituximab in common variable immunodeficiency
por: Pecoraro, Antonio, et al.
Publicado: (2019)

FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma
por: Kasamon, Yvette L., et al.
Publicado: (2017)

P060: Prognosis of patients with relapsed and refractory classic Hodgkin lymphoma after nivolumab discontinuation and efficacy of nivolumab retreatment
por: Fedorova, Liudmila, et al.
Publicado: (2022)

Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma
por: Fedorova, Liudmila V., et al.
Publicado: (2021)

Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma
por: Maruyama, Dai, et al.
Publicado: (2017)

A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma
por: Hanel, Walter, et al.
Publicado: (2023)

Disseminated Blastomycosis Presenting as Oligoarthritis, Pneumonia, and Skin Disease in an Immunocompetent Child
por: Schildt, Emily, et al.
Publicado: (2021)

Nivolumab for Methotrexate-associated Classic Hodgkin's Lymphoma in a Rheumatoid Arthritis Patient
por: Tanaka, Keisuke, et al.
Publicado: (2019)

P57 What are the outcomes of persistent oligoarthritis? A systematic review plan
por: Smith, Andrew, et al.
Publicado: (2022)

Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma
por: Maruyama, Dai, et al.
Publicado: (2020)

Transient oligoarthritis of the lower extremity following influenza B virus infection: Case report
por: Bruck, Normi, et al.
Publicado: (2010)

Erratum to “A case of de novo seronegative inflammatory oligoarthritis associated with COVID-19 infection” Clinical Immunology Communications 2 (2022) 159–161/
por: Sung, Lily H., et al.
Publicado: (2023)

Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab
por: De Filippi, Rosaria, et al.
Publicado: (2021)

Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA
por: Laliberté, François, et al.
Publicado: (2020)

IMMU-19. NIVOLUMAB-INDUCED CNS DEMYELINATION IN A 15-YEAR-OLD WITH CLASSIC HODGKIN LYMPHOMA
por: Ramirez, Alejandra, et al.
Publicado: (2023)

Common Variable Immunodeficiency and Autoimmune Diseases: A Retrospective Study of 95 Adult Patients in a Single Tertiary Care Center
por: Mormile, Ilaria, et al.
Publicado: (2021)

P1080: COMPARISON OF NIVOLUMAB 40 MG EFFICACY VERSUS 3 MG/KG IN PATIENTS WITH RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA
por: Fedorova, L., et al.
Publicado: (2022)

Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study
por: Ansell, Stephen M., et al.
Publicado: (2023)

P062: The efficacy and safety of nivolumab 40 mg therapy versus 3 mg/kg in patients with relapsed and refractory classic Hodgkin lymphoma
por: Fedorova, Liudmila, et al.
Publicado: (2022)

Immunosuppressive Treatment in Antiphospholipid Syndrome: Is It Worth It?
por: Mormile, Ilaria, et al.
Publicado: (2021)

Early Radiation-Induced Sarcoma in an Adolescent Treated for Relapsed Hodgkin Lymphoma with Nivolumab
por: Šalaševičius, Lukas, et al.
Publicado: (2020)

Mast Cells in Early Rheumatoid Arthritis
por: Rivellese, Felice, et al.
Publicado: (2019)

A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure
por: Lepik, Kirill V., et al.
Publicado: (2020)

Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
por: Voorhees, Timothy J, et al.
Publicado: (2020)

Checkpoint Inhibitors in Relapsed/Refractory Classical Hodgkin Lymphoma
por: Tarekegn, Kidist, et al.
Publicado: (2021)

Nivolumab in Relapsed/Refractory Classical Hodgkin Lymphoma – Extended Follow-up of 30 Patients Treated Within the CheckMate 205 Trial in a Single-Center
por: Momotow, Jesko, et al.
Publicado: (2019)

Efficacy of Brentuximab Vedotin and Nivolumab in Refractory or Relapsed Hodgkin Lymphoma: A Systematic Review
por: Macapagal, Sharina C, et al.
Publicado: (2022)

A Rare Case of HIV-Induced Neutropenia Resulting in Haemophilus influenzae Septic Oligoarthritis: A Case-Based Literature Review
por: Mahabadi, Navid, et al.
Publicado: (2022)

Nivolumab plus Brentuximab vedotin +/- bendamustine combination therapy: a safe and effective treatment in pediatric recurrent and refractory classical Hodgkin lymphoma
por: Greve, Patrick, et al.
Publicado: (2023)

IL-33 and Superantigenic Activation of Human Lung Mast Cells Induce the Release of Angiogenic and Lymphangiogenic Factors
por: Cristinziano, Leonardo, et al.
Publicado: (2021)

Genetics of classical Hodgkin Lymphoma
por: Schiavoni, Gianluca, et al.
Publicado: (2018)

Concurrent malignant melanoma and cutaneous involvement by classical hodgkin lymphoma (CHL) in a 63 year-old man
por: Gru, Alejandro A, et al.
Publicado: (2013)

Correction Notice: A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure
Publicado: (2021)

Nivolumab-Induced de novo Discoid Lupus Erythematosus
por: Manjunath, Jaya, et al.
Publicado: (2022)

Early Ear, Nose and Throat Manifestations in Eosinophilic Granulomatosis with Poliangioitis: Results from Our Cohort Group and Literature Review
por: D’Onofrio, Mario, et al.
Publicado: (2023)

The molecular mechanisms of classic Hodgkin's lymphoma.
por: Felberbaum, Rachael S.
Publicado: (2005)

Immunological Deregulation in Classic Hodgkin Lymphoma
por: Romano, Alessandra, et al.
Publicado: (2014)

Controversies in the Treatment of Classical Hodgkin Lymphoma
por: Eichenauer, Dennis A., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_t7lj5jmk13ju673pat10urk8e9